Hua Liu

Hua Liu


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2013 in BMC Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
JSJia-yi SUN
Jia-yi SUN
JLJian-Ping Liu
Jian-Ping Liu
KSKun-Ling Shen
Kun-Ling Shen
RMRong Ma
Rong Ma
ZCZhen-Ze Cui
Zhen-Ze Cui
ZWZi Wang
Zi Wang
Community-acquired pneumonia in children is common in China. To understand current clinical characteristics and practice, we conducted a cross-sectional study to analyze quality of care on childhood pneumonia in eight eastern cities in China.

4 August 2026 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
XHXiaoyun Hu
Xiaoyun Hu
YZYuning Zeng
Yuning Zeng
JLJunjie Li
Junjie Li
QLQiongxi Lin
Qiongxi Lin
ZLZixuan Liang
Zixuan Liang
HLHua Liu
Hua Liu
Objective: The relationship and underlying mechanisms linking the gut microbiota, metabolites and autism spectrum disorder (ASD) have not been fully elucidated. Methods: In the present study, network pharmacology was combined with machine learning for a systematic investigation into the possible action mechanisms between metabolites derived from the gut microbiota and their targets in ASD. Subsequently, untargeted metabolomics analysis and 16S rRNA sequencing were utilized for investigating alterations in differential metabolites and the composition of principal gut microbiota between normal and BTBR mice. Results: The findings demonstrated that five characteristic targets: CXCR3, HCAR2, HTR1A, IL-6 and NFKB1 modulated by the gut microbiota and gut microbiota’s metabolites were significantly associated with ASD. The M-S-M-T network prioritized 21 candidate gut-microbiota-derived metabolites, including phenylacetic acid and coumarin. These candidates were generated from database-based target prediction and should be interpreted separately from the differential metabolites detected in fecal metabolomics. Metabolomic and 16S rRNA sequencing analyses revealed that BTBR mice displayed metabolic dysregulation and disrupted gut microbiota composition compared with normal ones. These findings suggest that phenylalanine metabolism and neuroactive ligand-receptor interaction may be associated with ASD-like behavioral phenotypes in BTBR mice and warrant further experimental validation. The gut microbiota-metabolite-behavior network analysis further uncovered significant associations among the behavioral characteristics of ASD, alterations in gut microbiota composition and markedly altered metabolite profiles. Conclusion: By integrating network pharmacology, transcriptomic re-analysis, fecal metabolomics and 16S rRNA sequencing, this study identifies candidate microbe-metabolite-target associations related to ASD-like phenotypes. These results provide testable hypotheses for future mechanistic studies of gut-brain communication in ASD.

10 September 2026 in Frontiers in Pediatrics
Verified
Journal Article
Open access
PDF file
XLXiao-Xiao Lin
Xiao-Xiao Lin
YSYuan-Yuan Song
Yuan-Yuan Song
JXJia-Cheng Xue
Jia-Cheng Xue
HLHua Liu
Hua Liu
This study reports a pediatric patient harboring the heterozygous CDC42 variant (c. 203G > A, p. Arg68Gln), an ultra-rare variant with limited clinical and genetic data worldwide. She presented with typical Takenouchi-Kosaki syndrome (TKS) manifestations, including severe growth retardation, characteristic craniofacial dysmorphism, persistent macrothrombocytopenia and progressive sensorineural hearing loss. Additional evaluations identified leukopenia, hypogammaglobulinemia and a humoral immunodeficiency. Compound heterozygous GJB2 variants were detected but unlikely to dominate the patient's profound hearing loss. Off-label recombinant human growth hormone (rhGH) therapy was administered for her short stature. During six months of follow-up, favorable catch-up growth was achieved. Literature review was conducted to clarify features of this variant. This study supplements the clinical data of the CDC42 p. Arg68Gln variant, provides preliminary evidence for rhGH intervention, and offers reference information for the clinical management and genetic counseling of patients with TKS.